View in EDS

High dosage accelerated intermittent theta burst stimulation without precision targeting and dosing in depression: an open-label pilot study.

Saved in:
Bibliographic Details
Title: High dosage accelerated intermittent theta burst stimulation without precision targeting and dosing in depression: an open-label pilot study.
Authors: Chen, Miaoxi (AUTHOR), Björklund, Jonas (AUTHOR), Chang, Kai-Yen (AUTHOR), Burkhardt, Gerrit (AUTHOR), Bulubas, Lucia (AUTHOR), Weller, Simone (AUTHOR), Hagenah, Kristin (AUTHOR), Kesser, Daniel (AUTHOR), Brunoni, Andre R. (AUTHOR), Padberg, Frank (AUTHOR), Vogelmann, Ulrike (AUTHOR)
Source: European Archives of Psychiatry & Clinical Neuroscience. Mar2026, Vol. 276 Issue 2, p475-484. 10p.
Subjects: Mental depression, Brain stimulation, Neural stimulation, Mental health, Clinical trials, Antidepressants
Abstract: Background: High dosage accelerated intermittent theta-burst stimulation (aiTBS) protocols (10 sessions per day for 5 days) combined with precision targeting and depth adjusted iTBS intensity yield high response and remission rates in depression. However, disentangling their efficacy components to develop pragmatic mental health solutions is challenging. This pilot study applied such a high dosage aiTBS protocol without using any precision features. Methods: Eight patients with treatment-resistant depression (TRD) underwent open-label aiTBS targeting the left dorsolateral prefrontal cortex (DLPFC) using the Beam F3 algorithm. Over 5 days, patients received 50 aiTBS sessions, each delivering 1800 pulses at 90% resting motor threshold with 50-min inter-session intervals. All patients underwent a 4 weeks follow-up without stimulation, were offered tDCS for 4 weeks thereafter and had a final follow-up after 6 months. Treatment effects were assessed by clinical and cognitive measures. Results: Patients received 46 aiTBS sessions on average. At one-month follow-up, mean MADRS scores decreased by -12.50 ± 9.81 (Cohen's d = 2.83; 95% CI, 2.34–3.32; p < 0.001), with response and remission rates of 50% and 12.5%, respectively. After tDCS, 28.6% and 14.3% sustained response and remission, which declined to 16.7% and 0% at six months. Conclusion: This pilot trial evidenced the antidepressant effect of a high dosage aiTBS protocol comparable with the Stanford Neuromodulation Therapy (SNT) approach but without individualized precision components. Its effectiveness appeared lower than previously reported for SNT. Randomized controlled trials should systematically investigate the contribution of precision components to the overall effectiveness of aiTBS in depression. This trial is a part of a real-world clinical study of non-invasive brain stimulation treatments conducted at our department (preregistered at DRKS-ID: DRKS00024776, drks.de). [ABSTRACT FROM AUTHOR]
Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Background: High dosage accelerated intermittent theta-burst stimulation (aiTBS) protocols (10 sessions per day for 5 days) combined with precision targeting and depth adjusted iTBS intensity yield high response and remission rates in depression. However, disentangling their efficacy components to develop pragmatic mental health solutions is challenging. This pilot study applied such a high dosage aiTBS protocol without using any precision features. Methods: Eight patients with treatment-resistant depression (TRD) underwent open-label aiTBS targeting the left dorsolateral prefrontal cortex (DLPFC) using the Beam F3 algorithm. Over 5 days, patients received 50 aiTBS sessions, each delivering 1800 pulses at 90% resting motor threshold with 50-min inter-session intervals. All patients underwent a 4 weeks follow-up without stimulation, were offered tDCS for 4 weeks thereafter and had a final follow-up after 6 months. Treatment effects were assessed by clinical and cognitive measures. Results: Patients received 46 aiTBS sessions on average. At one-month follow-up, mean MADRS scores decreased by -12.50 ± 9.81 (Cohen's d = 2.83; 95% CI, 2.34–3.32; p < 0.001), with response and remission rates of 50% and 12.5%, respectively. After tDCS, 28.6% and 14.3% sustained response and remission, which declined to 16.7% and 0% at six months. Conclusion: This pilot trial evidenced the antidepressant effect of a high dosage aiTBS protocol comparable with the Stanford Neuromodulation Therapy (SNT) approach but without individualized precision components. Its effectiveness appeared lower than previously reported for SNT. Randomized controlled trials should systematically investigate the contribution of precision components to the overall effectiveness of aiTBS in depression. This trial is a part of a real-world clinical study of non-invasive brain stimulation treatments conducted at our department (preregistered at DRKS-ID: DRKS00024776, drks.de). [ABSTRACT FROM AUTHOR]
ISSN:09401334
DOI:10.1007/s00406-025-02067-z